DirectSens
Private Company
Funding information not available
Overview
DirectSens is a private Austrian biotech firm commercializing a proprietary 3rd generation biosensor platform based on direct electron transfer (DET) enzymes. The company targets two primary markets: healthcare diagnostics (e.g., lactate monitoring) and food & beverage quality control (e.g., sugar analysis). With ISO-certified manufacturing and a decade of R&D, DirectSens positions itself as a provider of end-to-end biosensor solutions that offer oxygen-independent, mediator-free operation for improved reliability and ease of use.
Technology Platform
3rd generation biosensor platform based on engineered enzymes capable of Direct Electron Transfer (DET), enabling oxygen-independent, mediator-free detection of analytes like sugars and lactate.
Opportunities
Risk Factors
Competitive Landscape
DirectSens competes in the broad biosensor market against major players like Abbott, Roche, and Siemens in diagnostics, as well as numerous other biotechnology startups. Its key differentiation is its proprietary 3rd generation DET enzyme technology, which it positions as more reliable and simpler than mediator-dependent 2nd generation systems.